PCSK9 and familial hypercholesterolemia: 429 Kazi Kazi DS DS Moran Moran AE AE Coxson Coxson PG PG Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease JAMA JAMA 2016 2016 316 316 7 7 743 743 753 753 27533159 27533159 Kazi DS, Moran AE, Coxson PG.